Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein

Molecular Pharmacology

Volumn 52, Issue 6, 1997, Pages 948-957

  Horton, Julie K ^a,d   Thimmaiah, Kuntebommanahalli N ^b   Altenberg, Guillermo A ^a   Castro, Ariel F ^a   Germain, Glen S ^c   Gowda, G Krishne ^b   Houghton, Peter J ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF MYSORE   (India)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIDOPINE; BISACRIDONE; CYCLOSPORIN A; GLYCOPROTEIN P; PROTEIN SYNTHESIS INHIBITOR; UNCLASSIFIED DRUG; VALSPODAR; VINBLASTINE;

ARTICLE; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG UPTAKE; GLYCOPROTEIN SYNTHESIS; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION;

EID: 0031453281     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.6.948     Document Type: Article

References (39)

1. Gottesman, M. M., and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427 (1993).
2. Goldstein, L. J. Clinical reversal of drug resistance. Curr. Probl. Cancer 19:65-124 (1995).
3. Dalton, W., and B. I. Sikic. The multi-drug resistance gene (MDR1) represents a potential target for reversing drug resistance in human malignancies. J. NIH Res. 6:54-58 (1994).
4. Houghton, P. J., and S. B. Kay. Multidrug resistance is not an important factor in therapeutic outcome in human malignancies. J. NIH Res. 6:55-61 (1994).
5. Campos, L., D. Guyotat, P. Archimbaud, P. Calmard-Oriol, T. Tsuruo, J. Troncy, D. Trielle, and D. Fiere. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476 (1992).
6. Chan, H. S. L., G. Haddad, P. S. Thorner, G. DeBoer, Y. P. Lin, N. Ondrusek, H. Yeger, and V. Ling. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 325:1608-1614 (1991).
7. Kuttesch, J. F., D. M. Parham, X. L. Luo, W. H. Meyer, L. Bowman, D. N. Shapiro, A. S. Pappo, W. M. Crist, W. T. Beck, and P. J. Houghton. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J. Clin. Oncol. 14: 886-900 (1996).
8. Grogan, T. M., C. M. Spier, S. E. Salmon, M. Matzner, J. Rybski, R. S. Weinstein, R. J. Scheper, and W. S. Dalton. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490-495 (1993).
9. Beck, W. T. Modulators of P-Glycoprotein-Associated Multidrug Resistance. Kluwer Academic Publishers, Norwell, MA (1991).
10. Ford, J. M. Modulators of multidrug resistance. Hematol. Oncol. Clin. North Am. 9:337-361 (1995).
11. Twentyman, P. R. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43:109-117 (1992).
12. te Boekhorst, P. A., J. van Kapel, M. Schoester, and P. Sonneveld. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 933 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother. Pharmacol. 30:238-242 (1992).
13. Qian, X.-D., and W. T. Beck. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res. 50:1132-1137 (1990).
14. Boesch, D., C. Gaveriaux, B. Jachez, A. Pourtier-Manzanedo, P. Bollinger, and F. Loor. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51:4226-4233 (1991).
15. Boote, D. J., P. R. Dennis, P. R. Twentyman, R. J. Osborne, C. Laburte, S. Hensel, J. F. Smyth, M. H. Brampton, and N. M. Bleehan. Phase I study with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14:610-618 (1996).
16. Altenberg, G. A., G. Young, J. K. Horton, D. Glass, J. A. Belli, and L. Reuss. Changes in intra-or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. Proc. Natl. Acad. Sci. USA 90:9735-9738 (1993).
17. Boesch, D., and F. Loor. Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anti-Cancer Drugs 5:229-238 (1994).
18. Thimmaiah, K. N., J. K. Horton, X.-D. Qian, W. T. Beck, J. A. Houghton, and P. J. Houghton. Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines. Cancer Commun. 2:249-259 (1990).
19. Shen, D.-W., A. Fojo, J. E. Chin, I. B. Roninson, N. Richert, I. Pastan, and M. M. Gottesman. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (Washington D. C.) 232:643-645 (1986).
20. Butler, W. B. Preparing nuclei from cells in monolayer cultures suitable for counting and for following synchronized cells through the cell cycle. Analyt. Biochem. 141:70-73 (1984).
21. Altenberg, G. A., M. Subramanyam, and L. Reuss. Muscarinic stimulation of gallbladder epithelium. III. Antagonism of cAMP-mediated effects. Am. J. Physiol. 267:C1196-C1202 (1994).
22. Pourcher, T., G. A. Altenberg, and L. Reuss. Heterologous expression of human P-glycoprotein (Pgp) using bacterial and baculovirus expression systems. FASEB J. 10:A92 (1996).
23. Sarkadi, B., E. M. Price, R. C. Boucher, U. A. Germann, and G. A. Scarborough. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267:4854-4858 (1992).
24. Horio, M., M. M. Gottesman, and I. Pastan. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 85:3580-3584 (1988).
25. Ambudkar, S. V. Purification and reconstitution of functional human P-glycoprotein. J. Bioenerg. Biomembr. 27:23-29 (1995).
26. Zacherl, J., G. Hamilton, T. Thalhammer, M. Riegler, E. P. Cosentini, A. Ellinger, G. Bischof, M. Schweitzer, B. Teleky, T. Koperna, and E. Wenzl. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother. Pharmacol. 34:125-132 (1994).
27. Naito, M., and T. Tsuruo. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res. 49:1452-1455 (1989).
28. Tamai, I., and A. R. Safa. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. Biol. Chem. 265:16509-16513 (1990).
29. Yusa, K., and T. Tsuruo. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ ADM cells. Cancer Res. 49:5002-5006 (1989).
30. Saeki, T., K. Ueda, Y. Tanigawara, R. Hori, and T. Komano. Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268: 6077-6080 (1993).
31. Archinal-Mattheis, A., R. W. Rzepka, T. Watanabe, N. Kokubu, Y. Itoh, N. J. Combates, K. W. Bair, and D. Cohen. Analysis of SDZ PSC 833 ([3́-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res. 7:603-610 (1995).
32. Rao, U. S., and G. A. Scarborough. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol. Pharmacol. 45:773-776 (1994).
33. Rao, U. S., R. L. Fine, and G. A. Scarborough. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem. Pharmacol. 48:287-292 (1994).
34. Ueda, K., N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. Komano, and R. Hori. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J. Biol. Chem. 267:24248-24252 (1992).
35. Eytan, G. D., R. Regev, G. Oren, and Y. G. Assaraf. The role of passive transbilayer drug drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271:12897-12902 (1996).
36. Broxterman, H. J., H. M. Pinedo, C. M. Kuiper, G. J. Schuurhuis, and J. Lankelma. Glycolysis in P-glycoprotein-overexpressing human tumor cell lines: effects of resistance-modifying agents. FEBS Lett. 247:405-410 (1989).
37. Twentyman, P. R., and N. M. Bleehan. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer 27: 1639-1642 (1991).
38. Fairchild, C. R., S. P. Ivy, C.-S. Kao-Shen, J. Whang-Peng, N. Rosen, M. A. Israel, P. W. Melera, K. H. Cowan, and M. E. Goldsmith. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res. 47:5141-5148 (1987).
39. Ludescher, C., W. Eisterer, W. Hilbe, J. Hofman, and J. Thaler. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br. J. Haematol. 91:652-657 (1995).